PediCAPis a 5-year research project focused on antibiotic therapy of severe and very severe childhood community acquired pneumonia
Through a collaboration between African and European partners it aims to provide data on optimal duration and oral step-down therapy for paediatric community acquired pneumonia.
Community-acquired pneumonia is common and remains associated with substantial morbidity and mortality, especially in lower and middle-income countries. In Africa very severe pneumonia has a mortality of 10-15% among children. Childhood pneumonia is also a leading cause of hospitalization.
Antibiotics are key to managing childhood pneumonia. WHO recommends injectable regimens, which cover a greater spectrum of bacterial pathogens but lead to longer hospital stays, high healthcare and societal costs, and to increased risks of nosocomial infections and acquisition of multidrug-resistant colonising bacteria. At present strong data to support a safe step-down to oral antibiotics, which would enable earlier discharge, are missing.
PediCAP aims to establish an active community of practice between the research teams and collaborators which will ensure the skills are in place to deliver a high-quality trial and associated sub-studies. Furthermore, PediCAP’s long-term goal is to equip the participating teams in the South and the North with lasting capability to run, lead and design their own studies beyond this project. The Global Health Network (University of Oxford) will have a key role in achieving these goals by providing them with a variety of trainings and with tools to support their collaboration and professional development.
Project Consortium / Partnership
Lead by Penta, PediCAP project builds on long-standing collaboration between European experts in pediatric clinical trials and clinical partners in sub-Saharan Africa. The PediCAP consortium will build on this expertise, aiming to engage a younger generation of paediatricians and scientists who could become the future leaders in paediatric antibiotic clinical trials, providing the evidence for future national and global optimal prescribing guidelines.
Start dateApril 1, 2019
First ethical approval obtained
First ethical approval obtainedJune 4, 2019
First patient enrolled
First patient enrolledJanuary 1, 2020
End of follow-up for all patients
End of follow-up for all patientsJanuary 1, 2021
First papers submitted to open access journal
First papers submitted to open access journalJanuary 1, 2022
End dateJanuary 1, 2023